Synergy between BRD9- and IKZF3-Targeting as a Therapeutic Strategy for Multiple Myeloma

Synergy between BRD9- and IKZF3-Targeting as a Therapeutic Strategy for Multiple Myeloma

Progress in the treatment of multiple myeloma (MM) has resulted in improvement in the survival rate. However, there is still a need for more efficacious and tolerated therapies. We and others have shown that bromodomain-containing protein 9 (BRD9), a member of the non-canonical SWI/SNF chromatin rem...

Full description

Bibliographic Details
Main Authors: Basudev Chowdhury, Swati Garg, Wei Ni, Martin Sattler, Dana Sanchez, Chengcheng Meng, Taisei Akatsu, Richard Stone, William Forrester, Edmund Harrington, Sara J. Buhrlage, James D. Griffin, Ellen Weisberg
Format: Article
Language:English
Published: MDPI AG 2024-03-01
Series:Cancers
Subjects:
IMiD
BRD9
degrader
multiple myeloma
synergy
Ikaros
Online Access:https://www.mdpi.com/2072-6694/16/7/1319

Internet

https://www.mdpi.com/2072-6694/16/7/1319

Similar Items